文献速递泌尿生殖与妇科肿瘤放疗

NRG Oncology/RTOG 0321长期结果:HDR近距离放疗联合外照射治疗前列腺腺癌的II期试验

Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-11-10

该II期多中心前瞻性试验评估前列腺癌患者接受外照射放疗(45 Gy/25次)联合高剂量率(HDR)近距离放疗(19 Gy/2次)的长期结局。中位随访10年,5年和10年总体生存率分别为95%和76%,生化失败率分别为14%和23%,晚期3级胃肠/泌尿生殖不良事件率为4%和5%,无4-5级晚期不良事件。结论认为该联合模式可获得优异的长期临床结局。

要点

  • 10年总体生存率76%,生化失败率23%,疾病特异性死亡率6%。
  • 5年和10年晚期3级胃肠/泌尿生殖不良事件率分别为4%和5%,无4-5级事件。

核心结论

  • 采用HDR前列腺近距离放疗的联合模式治疗在前瞻性多中心试验中可获得优异的长期临床结局。

研究设计与样本

  • NRG Oncology/RTOG 0321为II期前瞻性多中心试验,纳入临床局限期(T1c-T3b)前列腺癌患者,无经尿道前列腺切除或髋关节假体史。
  • 所有患者接受外照射放疗45 Gy/25次联合一次HDR植入 delivering 19 Gy/2次。

主要发现

  • 中位随访10年,6例(5%)患者出现3级胃肠和泌尿生殖治疗相关不良事件,无晚期4-5级胃肠和泌尿生殖不良事件。
  • 5年和10年晚期3级胃肠和泌尿生殖不良事件率分别为4%和5%。
  • 5年和10年总体生存率分别为95%和76%。
  • 按Phoenix定义的5年和10年生化失败率分别为14%和23%。
  • 10年疾病特异性死亡率为6%;5年和10年远处失败率分别为4%和8%,局部失败率均为2%。

临床怎么用

  • 对于临床局限期前列腺癌患者,外照射45 Gy/25次联合HDR近距离放疗19 Gy/2次可作为联合治疗选择,长期耐受性良好且肿瘤控制优异。

局限性

  • 为单臂II期试验,无随机对照组;不良事件数据仅115例可评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the long-term outcome of patients with prostate cancer treated with external beam radiation therapy and high dose rate (HDR) brachytherapy from a prospective multi-institutional trial conducted by NRG Oncology/RTOG. METHODS AND MATERIALS: Patients with clinically localized (T1c-T3b) prostate cancer without prior history of transurethral resection of prostate or hip prosthesis were eligible for this study. All patients were treated with a combination of 45 Gy in 25 fractions from external beam radiation therapy and one HDR implant delivering 19 Gy in 2 fractions. Adverse events (AE) were collected using Common Toxicity Criteria for Adverse Events, version 3. Cumulative incidence was used to estimate time to severe late gastrointestinal (GI)/genitourinary (GU) toxicity, biochemical failure, disease-specific mortality, local failure, and distant failure. Overall survival was estimated using the Kaplan-Meier method. RESULTS: One hundred and twenty-nine patients were enrolled from July 2004 to May 2006. AE data was available for 115 patients. Patients were National Comprehensive Cancer Network (NCCN) intermediate to very high risk. The median age was 68, T1c-T2c 91%, T3a-T3b 9%, PSA ≤10 70%, PSA >10 to ≤20 30%, GS 6 10%, GS 7 72%, and GS 8 to 10 18%. Forty-three percent of patients received hormonal therapy. At a median follow-up time of 10 years, there were 6 (5%) patients with grade 3 GI and GU treatment-related AEs, and no late grade 4 to 5 GI and GU AEs. At 5 and 10 years, the rate of late grade 3 gastrointestinal and genitourinary AEs was 4% and 5%, respectively. Five- and 10-year overall survival rates were 95% and 76%. Biochemical failure rates per Phoenix definition at 5 and 10 years were 14% and 23%. The 10-year rate of disease-specific mortality was 6%. At 5 and 10 years, the rates of distant failure were 4% and 8%, respectively. The rates of local failure at 5 and 10 years were 2% at both time points. CONCLUSIONS: Combined modality treatment using HDR prostate brachytherapy leads to excellent long-term clinical outcomes in this prospective multi-institutional trial.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hsu IC, Rodgers JP, Shinohara K, et al. Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate. Int J Radiat Oncol Biol Phys. 2020. PMID: 33186617. doi:10.1016/j.ijrobp.2020.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。